Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Retirement Systems of Alabama

Retirement Systems of Alabama lowered its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 190,077 shares of the specialty pharmaceutical company’s stock after selling 2,790 shares during the quarter. Retirement Systems of Alabama’s holdings in Jazz Pharmaceuticals were worth $21,176,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. CWA Asset Management Group LLC purchased a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at about $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Jazz Pharmaceuticals by 135.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after acquiring an additional 100,112 shares during the period. Pacer Advisors Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 15.3% in the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after acquiring an additional 278,465 shares during the last quarter. Philip James Wealth Mangement LLC acquired a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $830,000. Finally, Thompson Siegel & Walmsley LLC increased its holdings in Jazz Pharmaceuticals by 30.6% in the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 721,530 shares of the specialty pharmaceutical company’s stock valued at $77,009,000 after purchasing an additional 168,957 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the sale, the chief executive officer now owns 428,976 shares of the company’s stock, valued at approximately $47,547,699.84. This trade represents a 0.23 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the transaction, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,753 shares of company stock valued at $816,289 in the last ninety days. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $123.04 on Friday. The stock has a market cap of $7.44 billion, a P/E ratio of 17.33, a price-to-earnings-growth ratio of 1.02 and a beta of 0.57. The company has a fifty day simple moving average of $117.39 and a 200-day simple moving average of $112.16. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $134.17.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. HC Wainwright restated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Piper Sandler reissued an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday. TD Cowen dropped their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $140.00 to $175.00 in a research report on Thursday. Finally, Robert W. Baird lifted their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. Two investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $177.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.